Trial Profile
A Single Center, Open-label, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IM156 in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Jul 2022
Price :
$35
*
At a glance
- Drugs IM 156 (Primary)
- Indications Colorectal cancer; Endometrial cancer; Gastric cancer; Glioblastoma; Lymphoma; Ovarian cancer; Sarcoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors ImmunoMet Therapeutics
- 14 Jul 2022 According to a ImmunoMet Therapeutics media release, results from this study published in peer reviewed journal, Investigational New Drugs.
- 08 Jul 2022 Results published in the Investigational New Drugs
- 15 Oct 2020 Status changed from active, no longer recruiting to completed.